Search Results 41-50 of 9589 for N-Acetyl Selank

  1. Neurology - Clinical trials - Mayo Clinic

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  2. Publications - Jacob N. Clendenon, M.D. - Mayo Clinic

    Evaluation of the effects of N-acetylcysteine treatment in adult liver transplant patients JPSW. 2016; Nov/Dec 2016:49-52. Clendenon JN, Aranda-Michel J ...

  3. Clinical trials - Oncology (Medical)

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  4. Clinical trials - Oncology (Medical)

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  5. Neurosurgery - Clinical trials

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  6. Neurology - Clinical trials - Mayo Clinic

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  7. Clinical trials - Oncology (Medical)

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  8. Neurosurgery - Clinical trials

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...

  9. Ensartinib (oral route) - Side effects & dosage - Mayo Clinic

    Ensartinib is used to treat non-small cell lung cancer (NSCLC) that has spread in patients who have not received other medicines (eg, ALK-inhibitors) and whose ...

  10. Clinical trials - Oncology (Medical)

    ... N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring ...